1. SUB-TYPE OF MDS:Previously untreated higher-risk MDS, AML or CMML
2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
3. NAME OF DRUG: Glasdegib, Azacitidine
4. Aims and benefits: PGlasdegib disrupts cancer stem cell survival. This has the potential to reduce the development of drug resistance and prevent relapse. This is a Phase 1b study aimed at determining the safety and effectiveness of Glasdegib in combination with Azacitidine in this specific patient group.

1. Primary outcome measures: 
   Assessing complete remission rates and adverse events.
2. Secondary outcome measures:
   To determine response rates and the rates of haematologic improvement.
3. Basic inclusion criteria:
   • Clinical indication for treatment with Azacitidine.
   • Previously untreated higher-risk (Intermediate, high risk or very high risk) MDS, AML or CMML.
4. Basic exclusion criteria:
   • Patients with AML who are suitable for standard induction chemotherapy as first line treatment.
   • Known active CNS leukaemia.
   • Prior treatment with a smoothened inhibitor and/or a hypomethylating agent.
5. Trial sites/locations and name of physician in charge of trial:
   • Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
   • King’s College Hospital NHS Foundation Trust, London
   • Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne
   • Oxford University Hospitals NHS Foundation Trust, Oxford

Please read information and always discuss trial information with your own physician.